ICIs against programmed cell death protein 1 (PD-1), PD-L1, TIM-3 or CTLA-4 have made revolutionary advances in the treatment of HCC with prolonged OS and objective response rates [63]. The gene discussed is HAVCR2; the disease is hepatocellular carcinoma.